"This is an important step forward in our commercialization efforts and brings us closer to delivering this much-needed matrix technology for the emerging field of regenerative medicine," stated William P. Tew , PhD, Chief Commercialization Officer of BioTime, Inc. "The technology forms a foundation for the delivery of cell-based therapeutic products in both the adult and embryonic stem cell marketplace. Current preclinical studies at leading medical institutions have shown that HyStem® hydrogels are compatible with a wide variety of tissue types including brain, bone, skin, nerve, cartilage, and heart."
In the clinical application described in this CIP, ReneviaTM will be used as a delivery matrix for autologous adipose cells in order to restore subcutaneous tissue lost as a result of injury, oncologic resection, or congenital defects. Restoration of the normal skin contour is an important quality-of-life issue, not only in elective cosmetic procedures, but also in reconstructive surgeries needed to repair deformities and traumatic injuries to the face and upper extremities. BioTime's plan is to bring ReneviaTM to the medical market first in the European Union , where the regulatory pathway will allow for faster approval. Once the use of ReneviaTM is established in Europe , BioTime plans to address an even larger potential market in the United States .
Biotime has exploded since Dr. West (founder of Geron and ACTC) took over in 2007. I bought in back when it was 0.40. Looks like the winner in the stem sector right now, should know the fate of pure stem plays like CYTX in 2013.
Best of luck to all!
I was in BTX long ago when it was BTIM and Hextend was their main product.
Finally a big short squeeze made money for those of us who took the gift but the product never lived up to the promise of wide spread acceptance.
I dont see what they have now as a serious threat to CYTX at this point in time, if ever.
I'll stick with CYTX, warts and all !
One of the keys to Biotimes success in the area of reconstructive surgery will be their extra-cellular matrix IP. I don't know what the 'keys' of CYTX's success will be. I have always admired their website, marketing and PR. I'd like to ask CYTX investors what they think is their main advantage is at this point. I see many other companies with stem cells separation devices, but besides this fact i really have lost track of CYTX and would like to hear others opinions on this who might have insight.